At a Glance
  • Status: Completed Consortium
  • Year Launched: 2011
  • Initiating Organization: MRC/ABPI Inflammation and Immunology Initiative
  • Initiator Type: Government
  • Disease focus:
    Copd
  • Location: Europe

Abstract

COPDMAP, as part of the Medical Research Council (MRC)/Association of the British Pharmaceutical Industry (ABPI) Inflammation and Immunology Initiative, represents the first phase of a new approach in funding by the MRC, bringing together academics and industry at the early research and development stages to develop a stratified approach to disease (targeting the right treatments to the right people), enabling effective clinical trials as well as identifying novel biomarkers, mechanisms, and targets.

Structure & Governance

The following are COPDMAP Work Packages (WPs):

Financing

COPDMAP is funded by MRC and ABPI as part of the Inflammation and Immunology Initiative.

Sponsors & Partners

AstraZeneca

GlaxoSmithKline

Imperial College London

King’s College Hospital

NewCastle University

Novartis

Pfizer

Royal Brompton & Harefield

The University of Edinburgh

The University of Manchester

The University of Nottingham

The University of Sheffield

UCL (London’s Global)

University of Birmingham

University of Cambridge

University of Leicester

University of Liverpool

University of Southampton


Last Updated: 04/14/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.